Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash from Financing Activities for 9 consecutive years, with $192.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 4709.72% to $192.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $189.2 million, a 60.93% decrease, with the full-year FY2025 number at $189.2 million, down 60.93% from a year prior.
  • Cash from Financing Activities was $192.1 million for Q4 2025 at Denali Therapeutics, up from -$778000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $500.3 million in Q1 2024 to a low of -$18.6 million in Q3 2024.
  • A 5-year average of $51.1 million and a median of $4.1 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 31089.21% in 2024; the steepest drop was 844.74% in 2024.
  • Denali Therapeutics' Cash from Financing Activities stood at $5.2 million in 2021, then soared by 5698.2% to $299.7 million in 2022, then crashed by 98.43% to $4.7 million in 2023, then crashed by 188.59% to -$4.2 million in 2024, then surged by 4709.72% to $192.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash from Financing Activities are $192.1 million (Q4 2025), -$778000.0 (Q3 2025), and $1.6 million (Q2 2025).